Our main findings showed that a dose of vilazodone that suppressed the development of L-DOPA-induced dyskinesia also attenuated L-DOPA-induced gene regulation in direct pathway neurons (dMSNs), as demonstrated by the inhibition of the L-DOPA-induced increase in expression of the cell type marker dynorphin. This evidence concerns the gene PDYN and Dyskinesia.